Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remlarsen for Keloid Prevention
NCT03601052Phase 2Completed
- Sponsor
- Viridian Therapeutics
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of remlarsen in keloid, sponsored by Viridian Therapeutics. Started Jun 2018; status: completed.
02
Drugs
remlarsen
03
Conditions
keloid
Beyond the preview
Go deeper on NCT03601052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601052.